Shao Cui, Sun Mengxue, Liu Wanwen, Zhao Shaoyang, Liu Yang, Chen Yuna, Liang Shu-Nung, Yuan Haoyu, Sui Huacheng, Wang Baohua, Li Saimei
Department of Endocrinology, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Diabetes Metab Syndr Obes. 2022 Dec 23;15:4023-4033. doi: 10.2147/DMSO.S388336. eCollection 2022.
We aimed to assess the efficacy of the Jiang Tang San Huang (JTSH) tablet for the treatment of patients with type 2 diabetes mellitus (T2DM).
All data for this retrospective cohort study were acquired from the outpatient clinic database of our institution, and all enrolled patients received JTSH tablet for at least two months. Overall, 147 patients were included in the analysis. The primary outcome was patient-reported outcomes on the efficacy of the JTSH tablets using a questionnaire survey. Correlation analysis evaluated the duration of JTSH tablet administration and glycemic control in patients with T2DM. The secondary outcome measures included: changes in glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), 2-hour postprandial blood glucose, homeostasis model assessment of insulin resistance index (HOMA-IR) and homeostasis model assessment of β-cell function (HOMA-β) after 2 months of treatment with JTSH tablets.
Overall,120 patients (81.63%) reported a JTSH tablet treatment satisfaction score of ≥60 points, and believed that JTSH tablets had satisfactory hypoglycemic effects and could improve symptoms. The average duration of JTSH tablet treatment was 2.57±1.45 years. Overall, 111 patients achieved good blood glucose control, while 36 patients had poor glycemic control. Multivariate logistic regression model analysis showed that taking JTSH tablets for 1 year might reduce the risk of poor hypoglycemic effect by 17.00% (Risk ratio=0.830, 95% confidence interval:0.578, 1.021, =0.066). Compared with the baseline data, the levels of HbA1c, FPG and HOMA-IR decreased significantly and HOMA-β levels increased significantly (P<0.05).
Good blood glucose control may be positively correlated with the duration of JTSH tablets administration. Patients with T2DM were satisfied with the anti-diabetic effects of JTSH tablets, which can significantly reduce blood glucose and insulin resistance, and improve the function of islet cells.
我们旨在评估降糖三黄片治疗2型糖尿病(T2DM)患者的疗效。
这项回顾性队列研究的所有数据均来自我们机构的门诊数据库,所有纳入的患者均接受降糖三黄片治疗至少两个月。总体而言,147例患者纳入分析。主要结局是通过问卷调查患者报告的降糖三黄片疗效结果。相关性分析评估了降糖三黄片给药持续时间与T2DM患者血糖控制情况。次要结局指标包括:降糖三黄片治疗2个月后糖化血红蛋白(HbA1c)、空腹血糖(FPG)、餐后2小时血糖、胰岛素抵抗指数稳态模型评估(HOMA-IR)和β细胞功能稳态模型评估(HOMA-β)的变化。
总体而言,120例患者(81.63%)报告降糖三黄片治疗满意度评分≥60分,并认为降糖三黄片有满意的降糖效果且能改善症状。降糖三黄片治疗的平均持续时间为2.57±1.45年。总体而言,111例患者血糖控制良好,而36例患者血糖控制不佳。多因素逻辑回归模型分析显示,服用降糖三黄片1年可能使降糖效果不佳的风险降低17.00%(风险比=0.830,95%置信区间:0.578,1.021,P=0.066)。与基线数据相比,HbA1c、FPG和HOMA-IR水平显著下降,HOMA-β水平显著升高(P<0.05)。
良好的血糖控制可能与降糖三黄片的给药持续时间呈正相关。T2DM患者对降糖三黄片的降糖效果满意,其可显著降低血糖和胰岛素抵抗,并改善胰岛细胞功能。